Ohio voters reject measure that capped prices for drugs bought by the state; Senate Republicans consider keeping medical expense deduction in their tax bill; and the flu vaccine's effectiveness can be undermined by the process by which it is grown.
On election day 2017, Ohio voters rejected a measure that would curb prices of drugs bought by the state. AP reported that the measure would have ensured the state did not pay more than the Department of Veterans Affairs (VA) for prescription drugs. The VA often has deeply discounted drugs because it can negotiate prices. The pharmaceutical industry fought against the measure and put $70 million into ads attacking it.
The House tax reform bill excluded a popular medical expense deduction that Senate Republicans are considering having in their version of the tax bill. The deduction allows people to offset high healthcare costs by deducting large medical expenses in their individual income taxes, explained The Wall Street Journal. Senators Lisa Murkowski, R-Alaska, and Bill Cassidy, R-Louisiana, both noted the importance of this deduction for Americans. The Senate can only lose 2 Republican votes if it hopes to pass a bill.
This year may be one of those years when the flu vaccine offers less protection, and the process of creating vaccines may be the reason why. STAT provided an outline of how most flu vaccines are made: grown in eggs. While the process is inexpensive, it can cause issues that undermine the effectiveness of the vaccine. The vaccines are grown in hens’ eggs and mutate in order to grow, and a new study showed that last year’s disappointing vaccine was the result of a mutation that developed during the growth process in the egg.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More